Results 51 to 60 of about 50,960 (274)

Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.

open access: yesPLoS ONE, 2020
With the introduction of direct-acting antiviral (DAA) agents, hepatitis C virus (HCV) treatment has dramatically improved. However, there are insufficient data on the benefits of DAA therapy in hepatocellular carcinoma (HCC).
Wei-Chen Lin   +6 more
doaj   +1 more source

Analysis of UAS DAA Alerting in Fast-Time Simulations without DAA Mitigation [PDF]

open access: yes, 2015
Realization of the expected proliferation of Unmanned Aircraft System (UAS) operations in the National Airspace System (NAS) depends on the development and validation of performance standards for UAS Detect and Avoid (DAA) Systems.
Park, Chunki   +6 more
core  

Mechanochemically Disordered Li2Ta2OCl10 Oxyhalide Unlocks Superionic Conductivity (>10 mS.cm−1)

open access: yesAdvanced Energy Materials, EarlyView.
This work presents a new crystalline oxyhalide, Li2Ta2OCl10, built from [Ta2OCl10]2− dimers. The disorder induced by ball‐milling drives the dramatic 5000‐fold increase in ionic conductivity to reach 11 mS.cm−1. The material shows promise as a solid electrolyte for batteries and opens new prospects for the discovery of new dimer‐based compounds ...
Clément Morel   +11 more
wiley   +1 more source

Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C–Related Advanced Fibrosis and Cirrhosis

open access: yesJournal of Hepatocellular Carcinoma, 2021
Shimaa Kilany,1 Lmyaa Ata,1 Asmaa Gomaa,1 Aliaa Sabry,1 Ali Nada,1 El-Sayed Tharwa,1 Gamal Badra,1 Ashraf Abogabal,1 Mohamed Elwaraky,2 Enas Moaz,3 Sameera Ezzat,3 Ahmed Elsharawy,4 Imam Waked1 1Hepatology and Gastroenterology Department, National Liver ...
Kilany S   +12 more
doaj  

Re-transplantation outcomes for hepatitis C in the United States before and after DAA-introduction

open access: yes, 2020
The success of direct-acting antiviral (DAA) therapy has led to near-universal cure for patients chronically infected with hepatitis C virus (HCV) and improved post-liver transplant(LT) outcomes.
Al-Kurd, Abbas   +10 more
core   +1 more source

Vasoconstrictor and Pressor Effects of Des-Aspartate-Angiotensin I in Rat

open access: yesBiomedicines, 2022
This study investigated the vasoactive effects of des-aspartate-angiotensin-I (DAA-I) in male Wistar rats on whole body vascular bed, isolated perfused kidneys, and aortic rings.
Rosemary Wangensteen   +7 more
doaj   +1 more source

Defining the Collision Avoidance Region for DAA Systems [PDF]

open access: yes, 2016
Unmanned aircraft systems (UAS) will be required to equip with a detect-and-avoid (DAA) system in order to satisfy the federal aviation regulations to maintain well clear of other aircraft, some of which may be equipped with a Traffic Collision Avoidance
Park, Chunki   +4 more
core  

Dehydroabietic Acid Is a Novel Survivin Inhibitor for Gastric Cancer

open access: yesPlants, 2021
Gastric cancer is a malignant tumor with a high incidence and mortality rate worldwide. Nevertheless, anticancer drugs that can be used for gastric cancer treatment are limited.
Won-Jin Kim   +4 more
doaj   +1 more source

Plasma Proteome Reflects Tissue Damage and Clinical Manifestations in Patients With Inflammatory Myopathies

open access: yesArthritis &Rheumatology, EarlyView.
Objective Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins.
Yue‐Bei Luo   +23 more
wiley   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy